Keyphrases
Multiple Sclerosis
98%
Fracture Risk
97%
Population-based Cohort Study
64%
Hazard Ratio
51%
Insulin
39%
Osteoporotic Fractures
38%
Multiple Sclerosis Treatment
31%
Thiazolidinediones
31%
Confidence Interval
30%
National Health
30%
Health Registers
30%
Hip Fracture
29%
Insulin Analogues
29%
Pharmacoepidemiology
27%
Cancer Risk
25%
Ankylosing Spondylitis
25%
Meta-analysis
25%
Clinical Practice Research Datalink
23%
Adjusted Hazard Ratio
23%
Incidence Rate
21%
Multi-database
21%
Individual Patient Data
20%
Cox Proportional Hazards Model
18%
Population-based
17%
United Kingdom
17%
Database Study
16%
Drug Use
16%
General Practice Research Database
15%
Bladder Cancer
15%
Patients with Parkinson's Disease
15%
Human Insulin
15%
Breast Cancer Risk
15%
Cancer Inpatients
15%
Parkinson Patients
15%
Glargine
14%
Birth Timing
14%
Systematic Literature Review
13%
Ischemic Heart Disease
12%
Denmark
12%
Antidiabetic Drugs
12%
Odds Ratio
12%
Antidepressants
12%
Type 2 Diabetes Mellitus (T2DM)
11%
Retrospective Cohort Study
11%
Netherlands
11%
Patients with Diabetes
11%
Pancreatic Cancer
11%
Systematic Meta-analysis
11%
Epidemiology
11%
UK General Practice
11%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Sclerosis
100%
Cohort Study
75%
Diseases
34%
Fragility Fracture
34%
Hip Fracture
33%
Thiazolidinedione
31%
Insulin Analog
28%
Observational Study
27%
Diabetes Mellitus
22%
Malignant Neoplasm
21%
Breast Cancer
21%
Ankylosing Spondylitis
20%
Case-Control Study
16%
Parkinson's Disease
16%
Human Insulin
15%
Recombinant Human Insulin
15%
Colorectal Carcinoma
13%
Comorbidity
12%
Ischemic Heart Disease
12%
Non Insulin Dependent Diabetes Mellitus
11%
Infection
11%
Insulin Glargine
10%
Antidepressant
10%
Human Immunodeficiency Virus Infection
10%
Cataract
10%
Pharmacoepidemiology
10%
Non-Steroidal Anti-Inflammatory Drug
9%
Glucocorticoid
9%
Biguanide
7%
Pancreas Cancer
7%
Acute Heart Infarction
7%
HIV
7%
Mortality Rate
7%
Femur Fracture
6%
Risk Evaluation
6%
Breast Tumor
6%
Antidiabetic Agent
6%
Metformin
5%
Bladder Cancer
5%
Multiple Fracture
5%
Dopamine Receptor Stimulating Agent
5%
Adverse Drug Reaction
5%
Rivaroxaban
5%
Drug Development
5%
Psychotropic Agent
5%
Iridocyclitis
5%
Inflammatory Bowel Disease
5%
Psoriasis
5%
Fibrinogen
5%
Randomized Controlled Trial
5%
Medicine and Dentistry
Cohort Analysis
46%
Systematic Review
35%
Cancer Risk
33%
Meta-Analysis
30%
Diabetes Mellitus
22%
Ankylosing Spondylitis
20%
Breast Cancer
20%
Malignant Neoplasm
17%
Cohort Effect
16%
Diabetes
15%
Retrospective Cohort Study
15%
Hazard Ratio
14%
Patient with Diabetes
14%
Recombinant Human Insulin
14%
Human Insulin
14%
Colorectal Carcinoma
12%
Case-Control Study
11%
Insulin Treatment
11%
Bladder Cancer
10%
In Vitro
10%
Human Immunodeficiency Virus Infection
10%
Odds Ratio
10%
Patient-Data
9%
Observational Study
9%
Psoriasis
8%
Iridocyclitis
8%
Inflammatory Bowel Disease
8%
Breast Tumor
8%
Proportional Hazards Model
7%
Ischemic Heart Disease
7%
Antidiabetic Agent
7%
Insulin Glargine
7%
Nonsteroid Antiinflammatory Agent
6%
Pancreas Cancer
6%
Patient with Type 2 Diabetes
6%
Maturity Onset Diabetes of the Young
6%
Human Immunodeficiency Virus
6%
Body Mass Index
5%
Glycon
5%
Drug Use
5%
Cancer
5%
Logistic Regression Analysis
5%
Cardiovascular System
5%
Mental Health
5%
Biguanide Derivative
5%
Gastrointestinal Bleeding
5%
Incretin
5%
Knee Replacement
5%
Reproducibility
5%
Medicine
5%
